PepGen Seeks $125M Equity Raise Hours After Positive Phase 2 Data
PEPG has more than doubled off its 52-week low of $1.31 on elevated volume (41× avg).
Summary
PepGen launched a $125.0 million public offering of common stock and pre-funded warrants, with a 30-day underwriter option for up to $18.75 million more. The raise is large relative to the company's small market cap, so dilution is significant. Timing is notable: it lands the same day PepGen reported positive topline Phase 2 FREEDOM2-DM1 results at 10 mg/kg and disclosed $104.8 million in cash that funds operations into 2028. The company says proceeds will fund ongoing clinical development plus working capital. Leerink, Stifel and Guggenheim are joint bookrunning managers; pricing terms are not yet disclosed.
At the time of this announcement, PEPG was trading at $4.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $165.5M. The 52-week trading range was $1.31 to $7.80. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.